Please assess the completion status of the following clinical trial:

Trial Title: Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients older than 18 years of age, American Society of Anesthesiology (ASA) classification class I and II and assigned for elective resection of 2 or more liver segments portal hypertension~Exclusion Criteria:~* Patients with Child-Turcotte-Pugh grade B or C, clinically significant portal hypertension (splenomegaly, thrombocytopenia with platelets \< 1011/L, esophageal varices grade 2 or more), Preoperative renal failure (GFR \< 50ml/min), heart failure, Bradyarrhythmia (heart rate \< 60/min), history of hemorrhagic stroke, Uncontrolled arterial hypertension (Blood pressure \>160/100mmHg), and Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: ACTIVE_COMPARATOR): Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
- Control (Type: PLACEBO_COMPARATOR): same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).